COBALIS PRODUCT PIPELINE
PreHistin™ is intended to become the first-ever medication aimed specifically at rectifying imbalances in the immune system that trigger the over-production of allergy symptom-causing substances including histamines. By preventing or reducing the over-production of histamines before they are released, the need to block the symptom-causing effects of histamine is eliminated, as is the need to rely on antihistamines.
Cobalis’ approach makes good marketing sense when compared to the current paradigm of blocking the action of already-produced symptom-causing substances with antihistamines or other drugs, which often results in debilitating and uncomfortable side-effects. PreHistin™ as a preventative approach to allergic disease, becomes The World’s First Pre-Histamine™.
Our patents have broad claims covering all of the above-mentioned allergic diseases. The patents describe the use of cobalamin for reducing “…the symptoms and IgE antibodies associated with allergic diseases.”
Although Cobalis’ current research is focused on studying the effects of cyanocobalamin (the active ingredient in PreHistin™) on the reduction of symptoms associated with seasonal and perennial allergic rhinitis, we plan to sponsor clinical trials into other immunoglobulin-E (IgE)-mediated allergic diseases to expand our product line.
These supplemental indications include:
| :: |
Pediatric dosing for seasonal allergic rhinitis |
| :: | Allergic asthma |
| :: | Food allergies (including peanut) |
| :: |
IgE-mediated skin disorders (dermatitis, chronic urticaria, eczema, psoriasis) |
| :: | Allergic and migraine headache |
IMPORTANT NOTICE:
The FDA has not completed evaluation of PreHistin™, and the information and statements contained in this web site are intended for informational purposes only. They are not meant to imply a cure or approved treatment for any disease or condition. You are encouraged to consult your physician for any healthcare questions or concerns you may have about your allergies.
Copyright 2005-2006 Cobalis Corp.
Site Map
Design by www.de3ign.com
Created by BARDS
Cobalis Corp. (OTCBB: CLSC),
headquartered in Irvine, California, is dedicated to developing and bringing to the consumer marketplace unique
over-the-counter (OTC) products for the reduction, management and prevention of allergic diseases.
The Company’s premier product,
PreHistin™, represents Cobalis’
commitment to creating innovative new approaches to allergy management and to empowering consumers to take greater control of their health profiles.